SNCA and Parkinson disease: In summary, while the SPARK [5] and PASADENA [7] studies did not demonstrate efficacy of α-synuclein monoclonal antibodies in early PD, the results highlight the need to review potential limitations of preclinical studies and clinical trials from experimental models to endpoint assessments.